Table 1.

Recombinant Vesicular Stomatitis Virus Ebola Virus Glycoprotein Cross-Protective Efficacy in Rodent Models

	Mice MA-ZEBOV		Guinea Pigs GPA-ZEBOV
Vaccine	survival (n survival/n total)	Time to death (d)	Survival (n survival/n total)	Time to death (d)
Control	4/21	6.5 ± 1.5	0/6	7.3 ± 0.5
rVSVwt	5/21	5.6 ± 1.6	0/6	7.0 ± 0
rVSV-B-GP	n.d.	n.a.	1/6	9.4 ± 3.1
rVSV-CI-GP	22/22	n.a.	1/6	9.4 ± 2.3
rVSV-R-GP	20/20	n.a.	1/6	9.2 ± 2.5
rVSV-S Boniface-GP	15/20	6.8 ± 0.4	0/6	7.7 ± 0.5
rVSV-S Gulu-GP	n.d.	n.a.	0/6	7.8 ± 0.4
rVSV-Z Mayinga-GP	20/20	n.a.	6/6	n.d.
rVSV-Z Kikwit-GP	n.a.	n.a.	4/4	n.a.

NOTE. B = Bundibugyo ebolavirus (BEBOV); CI = Côte d'Ivoire ebolavirus (CIEBOV); GP = glycoprotein; GPA = guinea pig–adapted; MA - mouse-adapted; rVSV = recombinant vesicular stomatitis virus; R = Reston ebolavirus (REBOV); S = Sudan ebolavirus (SEBOV); wt = wild-type; Z = Zaire ebolavirus (ZEBOV); n.a., not applicable; n.d., not done.